5323052026-04-012026-06-305323052026-06-305323052026-04-012026-06-30in-capmkt:OtherExpenses1Member5323052026-04-012026-06-30AuditorDomain15323052026-06-30Statement15323052026-04-012026-06-30Statement15323052026-06-30StatementDynamic1I1Statement15323052026-06-30StatementDynamic1I2Statement15323052026-06-30StatementDynamic1I3Statement15323052026-06-30StatementDynamic1I4Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares532305INDSWFTLABNOTLISTEDINE915B01019IND-SWIFT LABORATORIES LIMITEDMain BoardEquity2026-04-012027-03-312026-08-102026-08-03INRLakhsQuarterlyFirst quarterSingle segmentPHARMACEUTICALS2026-08-1015:00:002026-08-1016:30:00Declaration of unmodified opiniontrue1falseNA2026-04-012026-06-30UnauditedStandalone1860824000762820001937106000817264000132679000-1978220003895350007051000758310003859330001610471000326635000-235800032427700079837000079837000024444000000002444400000244440000869616000102.812.81002.812.81Notes: - <br /> 1. During the quarter ended 30th June, 2026, the company has achieved an EBITDA of Rs. 33.32 Crores and earned a Standalone Net Profit of Rs. 24.44 Crores as compared to the EBITDA of Rs. 8.44 Crores and Standalone Net Profit of Rs. 8.12 Crores during the corresponding quarter of previous financial year. <br /> <br /> 2. The above Un-Audited Standalone and Consolidated Financial Results have been prepared considering the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 10th August, 2026. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified. <br /> <br /> 3. The Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30.06.2026 have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. <br /> <br /> 4. The figures for the quarter ended March 31, 2026 were the balancing figures between audited figures in respect of full financial year and the year-to-date figures upto the third quarter of the previous financial year. <br /> <br /> 5. Exceptional items for the quarter ended 30th June, 2026 is Rs. 23.58 Lakhs whereas for 31st March, 2026 comprise of Rs. 515.24 Lakhs and for the financial year ended 31st March, 2026 of Rs. 1100.64 Lakhs, towards balances written back/written off (net) on account of amounts no longer payable/receivable. <br /> <br /> 6. The Company has invested the available surplus funds in various investment avenues which is regularly being monitored by the Investment Committee duly constituted by the Board of Directors of the Company. <br /> <br /> 7. The Consolidated financial results include the financial results of the parent company, Ind-Swift Laboratories Limited and the financial results of the following subsidiaries/Joint Venture: <br /> a) Ind-Swift Laboratories Inc., USA (Subsidiary) <br /> b) Fortune (India) Constructions Limited (Subsidiary) <br /> c) Indis Healthcare LLP (Joint Venture) <br /> d) MJM Remedies Private Limited (Subsidiary) <br /> e) ISLL Middle East LLC-FZ (Subsidiary) <br /> f) Ind Swift India Limited Kenya (Subsidiary) <br /> g) Capital Strikers LLP (Joint Venture) <br /> Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as ‘the Group’. <br /> <br /> 8. No adjustment has been made in respect of Deferred Taxes as per Ind-AS 12, as the same would be provided at year end. <br /> <br /> 9. During the quarter under review the Company has not issued any Non-Convertible Debt Securities. <br /> <br /> 10. The previous period figures have been re-grouped and re-classified wherever necessary. <br /> <br /> 11. The Company is exclusively in the Pharmaceutical Business segment. <br /> <br /> <br /> <br /> <br /> <br /> Place: Panchkula For Ind-Swift Laboratories Limited <br /> <br /> <br /> <br /> <br /> Date: 10th August, 2026 Navrattan Munjal <br /> Chairman <br /> <br /> <br /> Other expenditure385933000000UnauditedtrueRATTAN KAUR AND ASSOCIATEStrue2027-01-31Preferential Issues2024-08-3025561130002026-06-30trueCARE RATINGS LIMITEDfalsePARDEEP VERMACompany Secretary and Compliance OfficerPANCHKULA2026-08-10Expansion of Business of the Company or the Wholly Owned Subsidiaries01500000000010977290000Investment in existing or to be acquired Subsidiaries050000000002747070000Working Capital for existing business039600000003960000000General Corporate Purpose075000000007500000000